Acrivon Therapeutics Director Palani Santhosh Receives 9,366 RSUs

This Form 4 filing reports that Palani Santhosh, a director of Acrivon Therapeutics, Inc., received 9,366 restricted stock units (RSUs) on May 18, 2026. The RSUs were granted at $0.00 per share and represent a contingent right to receive one share of common stock each. According to footnote F1, these RSUs will vest in full on May 18, 2027, subject to Santhosh's continuous service through that date. Following this transaction, Santhosh now holds 9,366 RSUs. The filing was signed by Adam D. Levy as Attorney-in-Fact on May 20, 2026. This transaction represents an equity award to a company director that aligns his interests with shareholders through future stock ownership.